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Correction to: Breast Cancer Res
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After publication of the original article [1], we were
notified that columns in Table 2 were erroneously
displayed.
The correction version of Table 2 is shown below.
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Table 2 Characteristics of cohort of BRCA1 and BRCA2 mutation carriers
BRCA1 mutation carriers BRCA2 mutation carriers
Unaffected
women
(N = 2003)
Women with
breast cancer
(N = 269)
Unaffected
women
(N = 1448)
Women with
breast cancer
(N = 157)
Total Person-years of follow-up 11,207 1134 7286 600
Person-years of follow-up (mean (sd)) 5.60 (3.67) 4.21 (3.27) 5.03 (3.44) 3.82 (3.08)
Age at start of follow-up (mean (sd)) 37.51 (11.80) 40.68 (10.25) 40.00 (12.53) 45.14 (10.11)
Age at diagnosis/censoring (mean (sd)) 43.10 (12.28) 44.90 (10.33) 45.00 (13.00) 48.97 (10.30)
Reason for censoring
Breast cancer 0 269 0 157
Ovarian cancer 49 3a 9 1a
Other cancer 45 5a 28 2a
RRM 299 – 181 –
Death 5 – 8 –
Unaffected at last follow-up time 1605 – 1222 –
Year of birth
< =1960 604 (83.54) 119 (16.46) 500 (84.75) 90 (15.25)
> 1960 1399 (90.32) 150 (9.68) 948 (93.40) 67 (6.60)
Menopausal status
Premenopausal at censoringb
Last informationc after censoring 512 69 344 35
Last information before censoringd 585 58 473 35
Postmenopausal
Natural menopause age known 194 27 182 31
Natural menopause age unknown 5 0 7 1
Post hysterectomy 70 12 64 11
Unknown menopausal status 62 13 33 8
RRSO status at censoring
No RRSO
Last information after censoring 664 110 467 79
Last information before censoring 618 44 535 27
RRSO 721 115 446 51
As reason for menopausee 574 90 345 36
After natural menopause 101 18 76 10
After hysterectomy 46 7 25 5
Abbreviations: RRSO Risk-Reducing Salpingo-oophorectomy, RRM Risk Reducing Mastectomy
aDiagnosed at the same time as breast cancer
bFifteen women did not report age at menopause but were older than 60 years at the end of follow-up
cInformation from questionnaire and record linkage
dAge last known to be premenopausal: mean 32.3 years, median 31 years for BRCA1 mutation carriers: mean 33.9, median 34 years for BRCA2 mutation carriers.
Time between this age and end of censoring: mean 6.3, median 5 years for BRCA1 and mean 6 years, median 5 years for BRCA2 mutation carriers
eSeven women reported RRSO after age 60 years without first reporting natural menopause
Mavaddat et al. Breast Cancer Research           (2020) 22:25 Page 3 of 3
